Top of this page
Skip navigation, go straight to the content
At UCB,
we aspire to be the patient-preferred biotech leader.
To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.
Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.
In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success.
2018 FY results
IR events
| Date | Event details |
|---|---|
| 19 June 2019 | Citi 8th Annual European Healthcare Conference, London1/1 meetings |
| 20 June 2019 | J.P. Morgan European Healthcare Conference 2019, London1/1 meetings |
| 25 July 2019 | 2019 half-year resultsMore details closer to the date |
Outlook 2019
2019 revenue reporting to reach approximately
€ 4.6-4.7 billion
Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of
27-29% of revenue
Core earnings per share are therefore expected in the range of
€ 4.40-4.80
based on an average of
188 million shares outstanding
Contact UCB IR team
investor-relations@ucb.com or a specific team member:
- Antje Witte, VP Investor Relations
Tel: +32 2 559 9414
E-mail: Antje.Witte@ucb.com - Isabelle Ghellynck, Associate Director Investor Relations
Tel: +32 2 559 9588
E-mail: Isabelle.Ghellynck@ucb.com - Nathalie Deldime, Investor Relations Events Manager
Tel: +32 2 559 9291
E-mail: Nathalie.Deldime@ucb.com
UCB IR App
